Search Results

Nobelpharma America, specialists in developing treatments and medical devices for rare diseases, announced it has received certification by Great Places to Work® for its values-based company culture and the quality of the workplace environment.

Partner Therapeutics, Inc. announced that its partner Nobelpharma received approval from the Japanese Pharmaceuticals and Medical Device Agency for the inhaled use of Leukine, branded in Japan as Sargmalin, to treat aPAP.

Nobelpharma America, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved HYFTOR™ (sirolimus topical gel) 0.2% as the first topical treatment indicated for facial angiofibroma associated with TSC in adults and children six (6) years of age or older1.

Nobelpharma America, LLC will debut HYFTOR ™ (sirolimus topical gel) 0.2%, the first-ever U.S. FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC) for patients 6 years and older at the 2022 World TSC Conference at the Hilton Anatole Hotel in Dallas, Texas, from July 28-31, 2022.

Nobelpharma America, LLC, a pharmaceutical and medical device company headquartered in Bethesda, Maryland, today announced its attendance at the American Epilepsy Society 2021 Annual Meeting, December 3-7, 2021.

Nobelpharma America, LLC, a pharmaceutical and medical device company headquartered in Bethesda, Maryland, announced the company received a National Sponsor award from the TSC Alliance recognizing the company’s support for the Step Forward to Cure TSC® event.

Nobelpharma America, LLC, a pharmaceutical and medical device company headquartered in Bethesda, Maryland, today announced its involvement at the 2021 Society for Pediatric Dermatology (SPD) Annual Meeting July 8-10, 2021.

Today, the Tuberous Sclerosis Alliance (TS Alliance) and Nobelpharma America, LLC (NPA) announced an ongoing collaboration.

Nobelpharma America, LLC has initiated distribution of HYFTOR™ (sirolimus topical gel) 0.2% into the United States healthcare marketplace.